CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 135 participants.
Also called NCT06959121
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 135 participants
- Sponsor
- Registry
-
NCT06959121
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06959121. Allocation not applicable; no masking; primary purpose treatment. Start 2025-10-23 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
- Acronym
- NANOCLAMP-AF
- Condition
- Atrial Fibrillation
- Condition
- Maze Procedure
- Condition
- AF
- Condition
- Ablation
- Intervention (Device)
- CellFX® nsPFA™ Cardiac Surgery System
- Lead sponsor
- Pulse Biosciences, Inc.
- Collaborator
- Avania
Record details
- Record id
cardio:ct-nct06959121- Content hash
8b2906febbc3bc78b5769b8f90ced10f9ca9a4fc0791b1f4de008f23a13b5b90